AI Article Synopsis

  • Proton pump inhibitors (PPI) are commonly used to prevent re-bleeding in high-risk peptic ulcer patients after endoscopic treatment, and this study compares their effectiveness to vonoprazan (VPZ), which can achieve similar gastric pH levels.
  • The study involved 44 patients with high-risk peptic ulcers, randomly assigned to receive either PPI or VPZ, and key outcomes measured included re-bleeding rates at different time intervals, blood transfusions needed, hospital stay duration, and ulcer healing rates.
  • Results showed a 9.1% re-bleeding rate in the PPI group within 72 hours compared to 0% in the VPZ group, but no significant differences were found

Article Abstract

: Proton pump inhibitor (PPI) therapy is well-established for its effectiveness in reducing re-bleeding in high-risk peptic ulcer patients following endoscopic hemostasis. Vonoprazan (VPZ) has demonstrated the capacity to achieve gastric pH levels exceeding 4, comparable to PPIs. This study aims to evaluate the comparative efficacy of intravenous PPI infusion versus VPZ in preventing re-bleeding after endoscopic hemostasis in patients with high-risk peptic ulcers. : A randomized, double-blind, controlled, and double-dummy design was employed. Patients with peptic ulcer bleeding (Forrest class IA/IB or IIA/IIB) who underwent endoscopic hemostasis were randomly assigned to either the PPI group or the VPZ group. Re-bleeding rates at 3, 7, and 30 days, the number of blood transfusions required, length of hospitalization, and ulcer healing rate at 56 days were assessed. A total of 44 eligible patients were enrolled, including 20 patients (PPI group, = 11; VPZ group, = 9) with high-risk peptic ulcers. The mean age was 66 years, with 70% being male. Re-bleeding within 72 h occurred in 9.1% of the PPI group versus 0% in the VPZ group ( = 1.000). There was no significant difference in re-bleeding rates within 7 days and 30 days (18.2% vs. 11.1%, = 1.000). Additionally, the ulcer healing rate did not significantly differ between the groups (87.5% vs. 77.8%). : This pilot study demonstrates comparable efficacy between oral vonoprazan and continuous PPI infusion in preventing recurrent bleeding events among high-risk peptic ulcer patients following successful endoscopic hemostasis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11204564PMC
http://dx.doi.org/10.3390/jcm13123606DOI Listing

Publication Analysis

Top Keywords

high-risk peptic
20
endoscopic hemostasis
16
peptic ulcers
12
peptic ulcer
12
ppi group
12
vpz group
12
proton pump
8
pump inhibitor
8
re-bleeding high-risk
8
ulcers randomized
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!